Assmann, Gerd

Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study

Assmann, G., Cullen, P., & Schulte, H. (2002) · Circulation

Lipoproteins and Cardiovascular HealthHealth Promotion and Cardiovascular Prevention

Cited by 1,541

Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1

Rust, S., Rosier, M., Funke, H., Real, J., Amoura, Z., Piette, J.-C., Deleuze, J.-F., Brewer, H. B., Duverger, N., Denèfle, P., et al. (1999) · Nature Genetics

Cholesterol and Lipid MetabolismDrug Transport and Resistance Mechanisms

Cited by 1,433

Association of cardiometabolic multimorbidity with mortality

Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., Butterworth, A. S., Bansal, N., O’Keeffe, L. M., Gao, P., Wood, A. M., Burgess, S., et al. (2015) · JAMA

Chronic Disease Management StrategiesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,155

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience)

Assmann, G., & Schulte, H. (1992) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 872

Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men

Heinrich, J., Balleisen, L., Schulte, H., Assmann, G., & van de Loo, J. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology

Blood properties and coagulationLipoproteins and Cardiovascular Health

Cited by 563

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 463

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients

Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 260

Overexpression and Accumulation of Apolipoprotein E as a Cause of Hypertriglyceridemia

Huang, Y., Liu, X. Q., Rall, S. C., Taylor, J. M., von Eckardstein, A., Assmann, G., & Mahley, R. W. (1998) · Journal of Biological Chemistry

Lipid metabolism and disordersCholesterol and Lipid Metabolism

Cited by 204

Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders

Onat, A., Hergenç, G., Sansoy, V., Fobker, M., Ceyhan, K., Toprak, S., & Assmann, G. (2003) · Atherosclerosis

Diabetes, Cardiovascular Risks, and LipoproteinsLipid metabolism and disorders

Cited by 134

Relation of serum levels of sex hormone binding globulin to coronary heart disease in postmenopausal women

Reinecke, H., Bogdanski, J., Woltering, A., Breithardt, G. Ü., Assmann, G., Kerber, S., & von Eckardstein, A. (2002) · The American Journal of Cardiology

Hormonal and reproductive studiesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 78

The importance of triglycerides: Results from the prospective cardiovascular M�nster (PROCAM) study

Assmann, G., & Schulte, H. (1992) · European Journal of Epidemiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 73

Apolipoprotein A-I-stimulated Apolipoprotein E Secretion from Human Macrophages Is Independent of Cholesterol Efflux

Kockx, M., Rye, K.-A., Gaus, K., Quinn, C. M., Wright, J., Sloane, T., Sviridov, D., Fu, Y., Sullivan, D., Burnett, J. R., et al. (2004) · Journal of Biological Chemistry

Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Cited by 47

Effects of a Frequent Apolipoprotein E Isoform, ApoE4 Freiburg (Leu28→Pro), on Lipoproteins and the Prevalence of Coronary Artery Disease in Whites

Orth, M., Weng, W., Funke, H., Steinmetz, A., Assmann, G., Nauck, M., Dierkes, J., Ambrosch, A., Weisgraber, K. H., Mahley, R. W., et al. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 42

Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and & epsilon;1/lsquo;null genotype‡

FEUSSNER, G., FUNKE, H., WENG, W., ASSMANN, G., LACKNER, K. J., & ZIEGLER, R. (1992) · European Journal of Clinical Investigation

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 28

Normolipemic dysbetalipoproteinemia and hyperlipoproteinemia type III in subjects homozygous for a rare genetic apolipoprotein E variant (apoE1).

Steinmetz, A., Assefbarkhi, N., Eltze, C., Ehlenz, K., Funke, H., Pies, A., Assmann, G., & Kaffarnik, H. (1990) · Journal of Lipid Research

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 27

Comparison of risk factors for coronary heart disease in Dresden and Münster: Results of the DRECAN (Dresden Cardiovascular Risk and Nutrition) study and the PROCAM (Prospective Cardiovascular Münster) study

Jaross, W., Assmann, G., Bergmann, S., Schulte, H., & DRECAN-Team (1994) · European Journal of Epidemiology

Cardiovascular Health and Risk FactorsHealthcare Systems and Public Health

Cited by 26